United Therapeutics Co. (UTHR) Holdings Trimmed by Meeder Asset Management Inc.
Meeder Asset Management Inc. lowered its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 25.7% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 6,526 shares of the biotechnology company’s stock after selling 2,252 shares during the period. Meeder Asset Management Inc.’s holdings in United Therapeutics were worth $766,000 at the end of the most recent reporting period.
A number of other large investors also recently bought and sold shares of the business. Louisiana State Employees Retirement System boosted its holdings in shares of United Therapeutics by 0.9% in the 1st quarter. Louisiana State Employees Retirement System now owns 11,700 shares of the biotechnology company’s stock valued at $1,373,000 after buying an additional 100 shares during the period. First Mercantile Trust Co. grew its holdings in shares of United Therapeutics by 47.8% in the 4th quarter. First Mercantile Trust Co. now owns 340 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 110 shares during the last quarter. Captrust Financial Advisors grew its holdings in shares of United Therapeutics by 384.9% in the 4th quarter. Captrust Financial Advisors now owns 257 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 204 shares during the last quarter. Daiwa Securities Group Inc. grew its holdings in shares of United Therapeutics by 13.2% in the 4th quarter. Daiwa Securities Group Inc. now owns 1,799 shares of the biotechnology company’s stock worth $196,000 after purchasing an additional 210 shares during the last quarter. Finally, Retirement Systems of Alabama grew its holdings in shares of United Therapeutics by 0.4% in the 4th quarter. Retirement Systems of Alabama now owns 56,512 shares of the biotechnology company’s stock worth $6,154,000 after purchasing an additional 214 shares during the last quarter. 97.66% of the stock is currently owned by institutional investors.
Shares of United Therapeutics stock opened at $100.34 on Friday. United Therapeutics Co. has a 1 year low of $98.77 and a 1 year high of $130.00. The firm has a market cap of $4.39 billion, a price-to-earnings ratio of 7.49 and a beta of 1.10. The company has a debt-to-equity ratio of 0.09, a current ratio of 6.39 and a quick ratio of 6.03.
In other news, CEO Martine A. Rothblatt sold 14,108 shares of United Therapeutics stock in a transaction on Monday, January 28th. The stock was sold at an average price of $115.37, for a total transaction of $1,627,639.96. Following the completion of the sale, the chief executive officer now owns 7,194 shares of the company’s stock, valued at $829,971.78. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Christopher Patusky sold 3,370 shares of United Therapeutics stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $110.75, for a total value of $373,227.50. The disclosure for this sale can be found here. Insiders have sold 46,094 shares of company stock valued at $5,284,325 in the last three months. Insiders own 8.20% of the company’s stock.
Several equities research analysts have recently weighed in on the stock. BidaskClub lowered shares of United Therapeutics from a “hold” rating to a “sell” rating in a report on Friday. ValuEngine lowered shares of United Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday. Oppenheimer lowered their target price on shares of United Therapeutics from $160.00 to $155.00 and set an “outperform” rating on the stock in a report on Tuesday, April 9th. Wedbush set a $269.00 target price on shares of United Therapeutics and gave the stock a “buy” rating in a report on Monday, April 8th. Finally, Credit Suisse Group reiterated an “underperform” rating and set a $98.00 price target (down previously from $105.00) on shares of United Therapeutics in a research report on Tuesday, March 26th. Four investment analysts have rated the stock with a sell rating, five have assigned a hold rating and three have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $133.11.
United Therapeutics Profile
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.
Featured Article: What is a bull market?
Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHR).
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.